

Form PTO-1595 (Rev. 07/05)
 OMB No. 0651-0027 (exp. 6/30/2008)

U.S. DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office

RECORDATION FORM COVER SHEET
PATENTS ONLY P9693US

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies) The BOC Group, Inc. Additional name(s) of conveying party(ies) attached? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		2. Name and address of receiving party(ies) Name: <u>Braker BioSpin GmbH</u> Internal Address: Street Address: <u>Silberstreifen</u> City: <u>D-76287 Rheinstetten</u> State: Country: <u>Germany</u> Zip: Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
3. Nature of conveyance/Execution Date(s): Execution Date(s) <u>October 09, 2008</u> <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Joint Research Agreement <input type="checkbox"/> Government Interest Assignment <input type="checkbox"/> Executive Order 9424, Confirmatory License <input type="checkbox"/> Other		4. Application or patent number(s): A. Patent Application No.(s) B. Patent No.(s) <u>7,084,627</u> <u>Patent Date August 01, 2006</u> This document is being filed together with a new application. Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
5. Name and address to whom correspondence concerning document should be mailed: Name: <u>Kohler Schmid Moebus</u> Street Address: <u>Ruppmannstrasse 27</u> City: <u>D-70565 Stuttgart</u> State: <u>Germany</u> Zip: Phone Number: <u>+49-711-78 47 30</u> Fax Number: <u>+49-711-7 80 09 96</u> Email Address: <u>stuttgart@ksmpatent.de</u>		6. Total number of applications and patents involved: 7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40 <input type="checkbox"/> Authorized to be charged by credit card <input checked="" type="checkbox"/> Authorized to be charged to deposit account <input type="checkbox"/> Enclosed <input type="checkbox"/> None required (government interest not affecting title)	
9. Signature: <u>Paul Vincent</u> Signature <u>Paul Vincent</u> Name of Person Signing		8. Payment Information a. Credit Card Last 4 Numbers _____ Expiration Date _____ b. Deposit Account Number <u>11-1447</u> Authorized User Name <u>Paul Vincent</u> December 22, 2008 Date Total number of pages including cover sheet, attachments, and documents: <u>11</u>	

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
 Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

CH \$40.00 111447 7084627

PATENT ASSIGNMENT

WHEREAS, The BOC Group, Inc., a Delaware corporation, having its principal office and place of business at 575 Mountain Avenue, Murray Hill, New Jersey 07974 USA, (hereinafter "Assignor") is the owner of the patents and patent applications identified on the attached Schedule A;

WHEREAS, Edwards Pharmaceutical Systems, Inc., a Delaware corporation, having its principal office and place of business at 575 Mountain Avenue, Murray Hill, New Jersey 07974 USA (hereinafter "Assignee") is desirous of acquiring said patents.

NOW, THEREFORE, TO WHOM IT MAY CONCERN, be it known that for good and valuable consideration, the receipt of which is hereby acknowledged by the Assignor, said Assignor by these presents does hereby sell, assign, and transfer to Assignee, its successors and assigns, as of March 1, 2006, its entire right title, and interest in and to said patents and patent applications, and in and to any and all reissues or extensions thereof or any patents or patent applications claiming priority therefrom. In respect of any patents or patent applications listed in Schedule A which are co-owned with any third party, such assignments will not take effect (if such assignment would be contrary to any agreement between the Assignor and the third party or prohibited under applicable law) until the written consent of the other co-owner has been obtained.

The BOC Group, Inc.
Mark Weller
By: _____
Mark Weller
General Counsel, North America

Attest: _____
State of New Jersey)
County of Union)

On this 27th day of April, 2006, before me a notary public in the State of New Jersey, personally appeared Mark Weller, to me personally known, who being by me duly sworn on oath did say that he is Vice President and General Counsel of said corporation, and that said instrument was signed and sealed in behalf of said corporation by authority of its Board of Directors and said acknowledged said instrument to be the free act and deed of said corporation.

CHARLES R. MORRISON JR.
NOTARY PUBLIC OF NEW JERSEY
Commission Expires 6/12/2011

Charles R. Morrison Jr.
Notary Public

Edwards Pharmaceutical Systems, Inc.

By: *David L. Brooks*

Attest: _____
State of New Jersey)
County of Union)

On this 23rd day of April, 2006, before me a notary public in the State of New Jersey, personally appeared David L. Brooks, to me personally known, who being by me duly sworn on oath did say that he is VP, Research of said corporation, and that said instrument was signed and sealed in behalf of said corporation by authority of its Board of Directors and said acknowledged said instrument to be the free act and deed of said corporation.

ELISABETH I. GASCHLER
NOTARY PUBLIC OF NEW JERSEY
My Commission Expires October 25, 2008

Elisabeth I. Gaschler
Notary Public

SCHEDULE A

Patent Family	Country	Issued Patents	Pending Applications
92A244	DE	69315726.7	93301911.9
92A244	EP	560632	93301911.9
92A244	ES	2110569	93301911.9
92A244	FI	108881	931120
92A244	FR	560632	93301911.9
92A244	GB	560632	93301911.9
92A244	IT	560632	93301911.9
92A244	JP	3245465	325153/92
92A244	US	5,689,898	08/610,817
92A244	US	5,519,946	07/849,846
93A474	AT	E193370	94307961.6
93A474	AU	672929	77548/94
93A474	BE	651212	94307961.6
93A474	BW	P861	
93A474	CA	2117858	2117858
93A474	CH	651212	94307961.6
93A474	DE	69424621.2	94307961.6
93A474	DK	651212	94307961.6
93A474	EP	651212	94307961.6
93A474	ES	2145811	94307961.6
93A474	FI	108232	945111
93A474	FR	651212	94307961.6
93A474	GB	651212	94307961.6
93A474	ID	ID0003282	P941746
93A474	IT	651212	94307961.6
93A474	JP	3577066	263895/94
93A474	KR	137914	94-28303
93A474	NA	94/0078	94/0076
93A474	NL	651212	94307961.6
93A474	SE	651212	94307961.6
93A474	SZ	RP/8/1996	
93A474	TH		24191
93A474	US	5,456,084	08/143,723
93A474	ZA	94/7831	94/7831
95A261	AT	E204514	96301569.8
95A261	AU	699042	45884/96
95A261	BE	730907	96301569.8
95A261	CN		96106100.6
95A261	DE	69614592.8	96301569.8
95A261	DK	730907	96301569.8
95A261	EP	730907	96301569.8
95A261	ES	ES2159684	96301569.8
95A261	FR	730907	96301569.8
95A261	GB	730907	96301569.8
95A261	IT	730907	96301569.8
95A261	JP		52859/96
95A261	NL	730907	96301569.8
95A261	SE	730907	96301569.8
95A261	US		08/401,390
95A261	US	5,783,156	08/682,250
96A459	BE	831286	97307277
96A459	CA	2215871	2215871
96A459	DE	69724540.3	97307277
96A459	EP	831286	97307277
96A459	FR	831286	97307277

96A458	GB	831286	97307277
96A458	JP		242582/97
96A459	RU	2191438	97116035
96A459	US	6,311,409	09/255,581
96A459	US	5,996,248	08/716,008
96A490	AT	E289871	97307278.8
96A490	BE	830896	97307278.8
96A490	CA	2212690	2212690
96A490	CH	830896	97307278.8
96A490	DE	69732596.2-08	97307278.8
96A490	EP	830896	97307278.8
96A490	ES	ES2235217T3	97307278.8
96A490	FR	830896	97307278.8
96A490	GB	830896	97307278.8
96A490	IE	830896	97307278.8
96A490	IT	830896	97307278.8
96A490	JP	3672704	239182/97
96A490	NL	830896	97307278.8
96A490	NO		19973892
96A490	TR		97/00977
96A490	US	5,892,200	08/716,007
M01A403	EP		2761327.2
M01A403	EP		4252232.6
M01A403	JP		2003-521080
M01A403	JP		2004-119933
M01A403	US	6,799,612	10/179,675
M01A403	US		10/418,087
M01A403	US		09/311,823
M01A403	US		US02/25517
M02A420	SG		200506965-3
M02A420	US		10/836,786
M02A420	US		10/471,231
M02A420	WO		US04/13218
M02A420	EP		04750890.8
M02A420	JP		2006-532503
M02A420	KR		2005-7021894
M02A422	CN		2.0048E+11
M02A422	EP		4750886.6
M02A422	JP		2006-532500
M02A422	KR		2005-7021883
M02A422	SG		200506929-9
M02A422	US	7,008,486	10/836,684
M02A422	US		10/471,414
M02A422	WO		US04/13214
M02A424	CN		2.0048E+11
M02A424	EP		4751187.7
M02A424	JP		2006-532542
M02A424	KR		2005-7021890
M02A424	SG		200506931-5
M02A424	US	6,946,838	10/837,108
M02A424	US		10/471125
M02A424	WO		US04/013705
M02A446	CN		2.0048E+11
M02A446	EP		4750887.4
M02A446	JP		2006-532501
M02A446	KR		2005-7021891
M02A446	SG		200506930-7
M02A446	US	7,015,883	10/836,738

M02A446	US		10/471,232
M02A446	WO		US04/013215
M03A244	US	7,002,348	10/881,930
M03A244	US		10/567,708
M03A244	WO		US04/020883
M03A244	CN		200480042904.5
M03A244	EP		04756354.9
M03A244	JP		Unknown
M03A244	KR		2006-7023109
M03A244	SG		200607336-5
M03A279	US		10/836,844
M03A279	WO		US04020890
M03A279	CN		200480042910.0
M03A279	EP		04756360.6
M03A279	JP		2007-510680
M03A279	KR		2006-7022578
M03A279	SG		200607337-3
M03A280	US		10/836,299
M03A280	WO		US04020889
M03A280	CN		200480042908.3
M03A280	EP		04756359.8
M03A280	JP		2007-510679
M03A280	KR		2006-7022485
M03A280	SG		200607339-9
M03A281	US		10/836,797
M03A281	WO		US04020882
M03A281	CN		200480042907.9
M03A281	EP		04756353.1
M03A281	JP		2007-510678
M03A281	KR		2006-7022691
M03A281	SG		200607340-7
M03A282	US		10/881,647
M03A282	US		10/567,929
M03A282	WO		US04020884
M03A282	CN		200480042945.4
M03A282	EP		04756355.6
M03A282	JP		Unknown
M03A282	KR		2006-7025222
M03A282	SG		200607344-9
M05A206	US		60/605382
M05A230	US		60/747018
M06A245	US		60/864612

State of Delaware
Secretary of State
Division of Corporations
Delivered 01:05 PM 03/17/2008
Filed 12:53 PM 03/17/2008
REV 080923780 - 4009378 FILE

**CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION
OF
BOC EDWARDS PHARMACEUTICAL SYSTEMS, INC.**

Pursuant to
§ 242 of the Delaware General Corporation Law

BOC Edwards Pharmaceutical Systems, Inc. (the "Corporation"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

FIRST: That the Board of Directors and sole shareholder of the Corporation, in accordance with the General Corporation Law of the State of Delaware (the "DGCL"), duly adopted resolutions setting forth the following amendment (the "Amendment") to the Certificate of Incorporation of the Corporation, declaring the Amendment to be advisable.

SECOND: That the Amendment was adopted by unanimous written consent of the directors of the Corporation followed by the unanimous written consent of the sole holder of the outstanding shares of common stock entitled to vote thereon, all in accordance with Sections 242, 141(f), and 228 of the DGCL.

THIRD: Accordingly, the Certificate of Incorporation of the Corporation is hereby amended by deleting in its entirety the present Article 1 and substituting in lieu thereof the following:

NY66111877/12725523

"1. The name of the corporation is IMA EDWARDS, INC."

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by José Ruiz, its Executive Vice President & General Manager, this 17th day of March, 2008.

**BOC EDWARDS PHARMACEUTICAL
SYSTEMS, INC.**

By: 
Name: José Ruiz
Title: Executive Vice President &
General Manager

IMA EDWARDS, INC

and

Bruker BioSpin GmbH

PATENT ASSIGNMENT

THIS ASSIGNMENT is made the 9TH day of Oct. 2008

BETWEEN:

1. **IMA EDWARDS INC** whose registered office is at 2175 Military Road, Tonawanda, New York, 14150 - USA (Trade Registry no. 20-3265112) (the "Assignor"); and
2. **Bruker BioSpin GmbH** whose registered office is at Silberstreifen D-76287 Rheinstetten, Germany (the "Assignee").

WHEREAS:

- (A) the Assignor is the owner of the Patents details of which are set out in the Schedule hereto (the "Patents").
- (B) The Assignor has agreed to assign its interests in the Patents to the Assignee.

NOW IT IS HEREBY AGREED AS FOLLOWS:

1. **Assignment**

The Assignor hereby assigns to the Assignee all its rights, title and interest in and to those Patents set out in the Schedule together with all the rights, privileges and advantages thereto including, without limitation, the right to take proceedings and recover damages and obtain all other remedies in respect of past infringements thereof to hold unto the Assignee absolutely.

2. **Amount**

The present Assignment is made for good and valuable consideration, the receipt of which is hereby acknowledged by the Assignor and for which the signature on the present deed is considered as a receipt.
The present Assignment relates to Patents in the field of NMR - NCCW technology, in which the Assignor has at moment no interest.

3. **Further Assurance**

The Assignor shall, at the Assignee's request and sole expenses, execute any further documents that may be necessary to secure the vesting in the Assignee of all rights assigned to the Assignee hereunder.


4. Governing Law

This Assignment shall be governed by and construed in accordance with the laws of the Republic of Italy and the parties hereby submit all the claims arising out from this Assignment to the exclusive jurisdiction of the Court of Bologna.

IN WITNESS WHEREOF this Assignment has been executed by or on behalf of the parties this 9th day of Oct. 2008.

Signed by GIOVANNI PECCHIOLI (PRESIDENT)
for and on behalf of

IMA EDWARDS INC



IMA EDWARDS

Signed by
for and on behalf of
Bruker BioSpin GmbH



Bruker BioSpin GmbH
Silberstreifen
D - 76287 Rheinstetten

Schedule
(Patents)

Patent Family	Country	Issued Patent	Status
M02A420	US	7,199,581	granted
M02A422	US	7,008,486	granted
M02A424	US	6,946,838	granted
M02A446	US	7,015,693	granted
M03A244	US	7,002,346	granted
M03A279	US	7,064,548	granted
M03A280	US	7,084,627	granted
M03A281	US	7,061,239	granted
M03A282	US	7,041,914	granted